A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis

Overview

Journal J Ophthalmic Vis Res

Specialty Ophthalmology

Date 2022 Jun 29

PMID 35765634

Authors

Neesurg S Mehta

Parisa Emami-Naeini

Affiliations

Soon will be listed here.

Abstract

Uveitis is one of the most common causes of vision loss and blindness worldwide. Local and/or systemic immunosuppression is often required to treat ocular inflammation in noninfectious uveitis. An understanding of safety and efficacy of these medications is required to individualize treatment to each patient to ensure compliance and achieve the best outcome. In this article, we reviewed the effectiveness of systemic biologic response modifiers and local treatments commonly used in the management of patients with noninfectious uveitis.

Citing Articles

Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.

Merzbach S, Schumacher-Klinger A, Klazas M, Hoffman A, Lazarovici P, Gilon C Invest Ophthalmol Vis Sci. 2025; 66(1):13.

PMID: 39775697 PMC: 11724373. DOI: 10.1167/iovs.66.1.13.

Targeting ocular tissues with intravenously administered aptamers selected by SELEX.

Korhonen S, Stenberg K, Seemab U, Bartos P, Makiniemi K, Kjems J Mol Ther Nucleic Acids. 2024; 35(4):102352.

PMID: 39469668 PMC: 11513532. DOI: 10.1016/j.omtn.2024.102352.

Seronegative spondyloarthropathy-associated inflammatory bowel disease.

Wang C, Tsai H World J Gastroenterol. 2023; 29(3):450-468.

PMID: 36688014 PMC: 9850936. DOI: 10.3748/wjg.v29.i3.450.

Multifunctional Interleukin-24 Resolves Neuroretina Autoimmunity via Diverse Mechanisms.

Zhang X, Hu C, Zhong Y, Qiao D, Chi W, Shen H Int J Mol Sci. 2022; 23(19).

PMID: 36233291 PMC: 9570500. DOI: 10.3390/ijms231911988.

References

You C, Sahawneh H, Ma L, Kubaisi B, Schmidt A, Foster C . A review and update on orphan drugs for the treatment of noninfectious uveitis. Clin Ophthalmol. 2017; 11:257-265. PMC: 5298311. DOI: 10.2147/OPTH.S121734. View

Langley R, Lebwohl M, Krueger G, Szapary P, Wasfi Y, Chan D . Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2014; 172(5):1371-83. DOI: 10.1111/bjd.13469. View

Fleischmann R, Genovese M, Lin Y, St John G, van der Heijde D, Wang S . Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Rheumatology (Oxford). 2019; 59(2):292-302. PMC: 7571482. DOI: 10.1093/rheumatology/kez265. View

Mugheddu C, Atzori L, Del Piano M, Lappi A, Pau M, Murgia S . Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017; 30(5). DOI: 10.1111/dth.12527. View

Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V . Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2013; 22(2):90-5. DOI: 10.3109/09273948.2013.844265. View

Simonini G, Druce K, Cimaz R, Macfarlane G, Jones G . Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014; 66(7):1073-84. DOI: 10.1002/acr.22214. View

Deuter C, Zierhut M, Igney-Oertel A, Xenitidis T, Feidt A, Sobolewska B . Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment. Ocul Immunol Inflamm. 2016; 25(2):215-220. DOI: 10.3109/09273948.2015.1099680. View

Jabs D, Nussenblatt R, Rosenbaum J . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140(3):509-16. PMC: 8935739. DOI: 10.1016/j.ajo.2005.03.057. View

Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G . Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018; 37(8):2233-2240. DOI: 10.1007/s10067-018-4119-x. View

10.

Kempen J, Altaweel M, Holbrook J, Jabs D, Sugar E . The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010; 149(4):550-561.e10. PMC: 2975449. DOI: 10.1016/j.ajo.2009.11.019. View

11.

Knickelbein J, Tucker W, Bhatt N, Armbrust K, Valent D, Obiyor D . Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. Am J Ophthalmol. 2016; 172:104-110. PMC: 5121021. DOI: 10.1016/j.ajo.2016.09.017. View

12.

Sharon Y, Chu D . Certolizumab pegol - Tumor necrosis factor inhibitor for refractory uveitis. Am J Ophthalmol Case Rep. 2020; 18:100633. PMC: 7068621. DOI: 10.1016/j.ajoc.2020.100633. View

13.

Erckens R, Mostard R, Wijnen P, Schouten J, Drent M . Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2011; 250(5):713-20. PMC: 3332360. DOI: 10.1007/s00417-011-1844-0. View

14.

Ibrahim M, Sepah Y, Watters A, Bittencourt M, Vigil E, Do D . One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis. Transl Vis Sci Technol. 2015; 4(2):4. PMC: 4356037. DOI: 10.1167/tvst.4.2.4. View

15.

Kotter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Gunaydin I . Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003; 87(4):423-31. PMC: 1771623. DOI: 10.1136/bjo.87.4.423. View

16.

Vitale A, Emmi G, Lopalco G, Fabiani C, Gentileschi S, Silvestri E . Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. Clin Rheumatol. 2017; 36(9):2063-2069. DOI: 10.1007/s10067-017-3627-4. View

17.

Calvo-Rio V, Santos-Gomez M, Calvo I, Gonzalez-Fernandez M, Lopez-Montesinos B, Mesquida M . Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol. 2016; 69(3):668-675. DOI: 10.1002/art.39940. View

18.

Lim L, Fraunfelder F, Rosenbaum J . Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007; 56(10):3248-52. DOI: 10.1002/art.22918. View

19.

Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C . Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018; 77(8):1107-1117. PMC: 6059050. DOI: 10.1136/annrheumdis-2018-213131. View

20.

Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S . Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease. Ann Rheum Dis. 2012; 71(9):1589-91. DOI: 10.1136/annrheumdis-2012-201383. View